ALK and non-small cell lung carcinoma: In the phase 3 trial PROFILE 1014, which granted the drug approval in Brazil and many other countries for ALK-positive NSCLC patients, 14% of patients in the crizotinib arm developed grade 3 transaminases elevation [5].